Cynata Therapeutics Limited (ASX:CYP) Reports Positive DFU Trial Results
Clinical Trial Results
Cynata Therapeutics Limited (ASX:CYP) has successfully completed its Phase 1 clinical trial of CYP-006TK for diabetic foot ulcers (DFU). The trial demonstrated that CYP-006TK is both safe and well-tolerated, with no participants withdrawing due to adverse events. Significant efficacy data showcased improved wound healing when compared to the standard of care control group.
Key Performance Indicators
After 12 weeks, the CYP-006TK group exhibited a mean decrease in wound surface area of 181 mm², while the control group showed an increase of 355 mm². At the end of the 24-week period, the CYP-006TK group achieved a decrease of 261 mm² compared to an increase of 62 mm² in the control group. Notably, the treatment group demonstrated a mean percentage reduction in wound area of 64.6% at 12 weeks and 83.6% at 24 weeks, contrasting with 22.0% and 47.8% in the control group.
CEO Comments
Dr Kilian Kelly, CEO and Managing Director of Cynata, expressed his satisfaction with the trial outcomes, stating, “We are very pleased and encouraged by these results. First and foremost, the trial achieved its primary objective of safety. Furthermore, while the trial was not powered to show statistically significant efficacy, we believe there is a clear signal indicating improved wound healing compared to standard treatments.”
Future Developments
The company plans to engage with regulatory agencies and potential commercial partners to further the development of CYP-006TK. Cynata awaits results from three more clinical trials expected within the next 18 months, enhancing the commercial potential of its Cymerus™ platform technology.
Motley Fool contributor Kiarra Jackson has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
This article was generated using GPT-4o mini, a Large Language Model (LLM), to generate summaries of investing news. While AI is generating the content, we know better than to blindly trust our future robot overlords, and every article is edited and fact-checked by an editor holding the appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content of everything published by The Capital Club.